BioInvest In The News

Top Picks 2017: Madrigal (1-20-2017)
Top Picks 2017: The Medicines Company (1-18-2017)
Top Picks 2017: Incyte (1-06-2017)
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
Incyte: A Promising Pipeline (11-14-2016)
Company Updates
Ionis (IONS) 5-15-17

Ionis (IONS) 5-15-17

BioInvest News – IONS – Reports Positive TTR Data, Safety/Patient Death Causes Concern – IONS reported positive Phase III data for inotersen (TTR-Rx) NEURO-TTR results in familial amyloid polyneuropathy (FAP) patients showing a statistically significant benefit in the two co-primary endpoints of modified Neuropathy Impairment Score (mNIS+7, p<0.0001) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN, P=0.0006) post 15 months of treatment.

Sangamo (SGMO) 5-10-17

Sangamo (SGMO) 5-10-17

Breaking News – Sangamo Therapeutics (SGMO) – PFE Global Deal for Hemophilia A Has Many Positive Implications – In a very competitive bidding process SGMO has inked a significant global partnership with Pfizer, who brings a wealth of value to SGMO, and notably validates the latter company’s gene therapy platform.

The Medicines Company (MDCO) 04-26-17

The Medicines Company (MDCO) 04-26-17

BIOINVEST BREAKING NEWS – The Medicines Company (MDCO) – Inclisiran FDA Path Clear After End of Phase II Meeting – Lower Risk, Value Enhanced – The Medicines Company announced that the primary endpoint of the Phase III registrational trial will be LDL-C levels. This is a major positive for MDCO – significantly reduces the risk and increases the value of Inclisiran.